Topics

Huons enters biosimilar market while private equity firm PAG invests in Hisun BioRay

06:14 EDT 13 Sep 2019 | Generics and Biosimilars Initiative

Huons has announced its plans to enter the biosimilar market, and private equity firm PAG has acquired a controlling interesting in Hisun Pharmaceutical’s biopharmaceutical subsidiary, Hisun BioRay.

Original Article: Huons enters biosimilar market while private equity firm PAG invests in Hisun BioRay

NEXT ARTICLE

More From BioPortfolio on "Huons enters biosimilar market while private equity firm PAG invests in Hisun BioRay"

Quick Search

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...